Group 1 - Arbutus Biopharma (ABUS) has gained approximately 60.8% year-to-date, outperforming the Medical sector average gain of 9.7% [2][3] - The Zacks Consensus Estimate for ABUS' full-year earnings has increased by 2.6% in the past quarter, indicating stronger analyst sentiment and an improving earnings outlook [2] - Arbutus Biopharma is ranked 6 in the Zacks Sector Rank and has a Zacks Rank of 2 (Buy), suggesting a favorable investment outlook [1][2] Group 2 - Arbutus Biopharma is part of the Medical - Biomedical and Genetics industry, which has seen an average loss of 0.3% year-to-date, highlighting ABUS's relative strength in this sector [3] - Astrazeneca (AZN), another outperforming stock in the Medical sector, has gained 14.1% year-to-date and has a Zacks Rank of 2 (Buy) [2][3] - The Large Cap Pharmaceuticals industry, to which Astrazeneca belongs, has performed well with a year-to-date increase of 22.7% [3]

Group 1 - Arbutus Biopharma (ABUS) has shown a year-to-date return of approximately 54.8%, significantly outperforming the Medical sector average return of 11.2% [2][3] - The Zacks Consensus Estimate for ABUS's full-year earnings has increased by 2.6% over the past quarter, indicating improved analyst sentiment [2] - Arbutus Biopharma is ranked 5 in the Zacks Sector Rank, which includes 1018 companies in the Medical group [1] Group 2 - Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry, which has an average year-to-date return of 3.3% [3] - Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) has a year-to-date return of 24.8% and is also ranked 2 (Buy) by Zacks [2][3] - The Medical - Drugs industry, to which Chugai belongs, has experienced a decline of -0.3% this year [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to | --- | --- | --- | --- | |------------------------------------------------------------------------------|------------------------------------------------------------- ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Arbutus Biopharma (ABUS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Arbutus Biopharma is one of 1021 individual stocks in the Medical sector ...

Biotechnology firm Arbutus (NASDAQ:ABUS) — which specializes in virology — announced a major overhaul of its business. It will dramatically cut headcount in an effort to streamline operations and focus on its most promising therapeutic candidates. The Arbutus layoffs will result in a 40% reduction in the company’s workforce. Though steep, ABUS stock gained about 1% in the early afternoon session.According to a MarketWatch report, the notable aspect of the shakeup is that Arbutus “plans to cease all Hepatiti ...

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2024 Earnings Conference Call August 1, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Michael McElhaugh - Interim President, CEO & Director Karen Sims - Chief Medical Officer David Hastings - CFO Conference Call Participants Dennis Ding - Jefferies Roy Buchanan - JMP Securities Keay Nakae - Chardan Capital Markets Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Second Quarter Financial Resul ...

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.10 per share when it actually produced a loss of $0.10, delivering no surprise.Over the last four quarters, the company has ...

EXHIBIT 99.1 Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I clinical trial demonstrated undetectable HBsAg in 33% of patients who were treated with 48 weeks of imdusiran and 24 weeks of IFN and in 67% of these patients with baseline HBsAg less than 1000 IU/mL Prioritizing imdus ...

WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its second quarter 2024 financial results and corporate update for Thursday, August 1, 2024. The schedule for the press release and conference call/webcast are as follows: •Q2 2024 Press Release:Thursd ...

In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation.In the IM-PROVE II trial, conducted in partnership with Arbutus Biopharma, a statistically significant difference was observed in HBsAg levels between the VTP-300 treatment and placebo groups at 24-weeks post-end of treatment (EOT) and 84% of ...